Using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas at ASCO GI 2016
Author: ASCOGI2016
Added: 01/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 27, 2016 Category: Cancer & Oncology Source Type: podcasts
ToGA trial and how it changed the management of HER2+ gastric carcinoma ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses the ToGA trial and how it changed the management of HER2+ gastric carcinoma at ASCO GI 2016
Author: ASCOGI2016
Added: 01/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 27, 2016 Category: Cancer & Oncology Source Type: podcasts
GATSBY trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma at ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses GATSBY trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma at ASCO GI 2016
Author: ASCOGI2016
Added: 01/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 27, 2016 Category: Cancer & Oncology Source Type: podcasts
FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or without bevacizumab in gastric carcinomas at ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or without bevacizumab in gastric carcinomas at ASCO GI 20...
Author: ASCOGI2016
Added: 01/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 27, 2016 Category: Cancer & Oncology Source Type: podcasts
FOLFOX + ziv-aflibercept adding anti-angiogenic agent to chemotherapy in advanced gastric adenocarcinoma ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses FOLFOX + ziv-aflibercept adding anti-angiogenic agent to chemotherapy in advanced gastric adenocarcinoma at ASCO GI 2016
Author: ASCOGI2016
Added: 01/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 27, 2016 Category: Cancer & Oncology Source Type: podcasts
ASCO GI 2016: Phase II-III trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma
Joel Randolph Hecht, MD of UCLA Health discusses phase II-III trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma at ASCO GI 2016
Author: ASCOGI2016
Added: 01/23/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 23, 2016 Category: Cancer & Oncology Source Type: podcasts
ASCO GI 2016: How did the ToGA trial changed the management of HER2+ gastric carcinoma
Joel Randolph Hecht, MD of UCLA Health discusses how did the ToGA trial changed the management of HER2+ gastric carcinoma at ASCO GI 2016
Author: ASCOGI2016
Added: 01/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 23, 2016 Category: Cancer & Oncology Source Type: podcasts
ASCO GI 2016: FOLFOX + ziv-aflibercept placebo adding anti-angiogenic agent to chemotherapy in advanced gastric and GE junction adenocarcinoma
Joel Randolph Hecht, MD of UCLA Health discusses ASCO GI 2016: FOLFOX + ziv-aflibercept placebo adding anti-angiogenic agent to chemotherapy in advanced gastric and GE junction adenocarcinoma at ASCO ...
Author: ASCOGI2016
Added: 01/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 23, 2016 Category: Cancer & Oncology Source Type: podcasts
ASCO GI 2016: The future of gastric cancers will be targeted agents including immunotherapy
Manish Shah, MD of Weill-Cornell Medical Center states that the future of gastric cancers will be targeted agents including immunotherapy at ASCO GI 2016
Author: ASCOGI2016
Added: 01/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 22, 2016 Category: Cancer & Oncology Source Type: podcasts
ASCO GI 2016: Sstandard of care for good performance status patients with advanced gastric adenocarcinomas
Manish Shah, MD of Weill-Cornell Medical Center discusses the standard of care for good performance status patients with advanced gastric adenocarcinomas at ASCO GI 2016
Author: ASCOGI2016
Added: 01/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 22, 2016 Category: Cancer & Oncology Source Type: podcasts
ASCO GI 2016: Phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma
Manish Shah, MD of Weill-Cornell Medical Center discusses the phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma at ASCO GI 2016
Author: ASCOGI2016
Added: 01/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 22, 2016 Category: Cancer & Oncology Source Type: podcasts
ASCO GI 2016: FOLFIRI versus FOLFOX7 will this randomized trial advance the treatment paradigms for advanced gastric cancer
Manish Shah, MD of Weill-Cornell Medical Center, NYC discusses FOLFIRI versus FOLFOX7 will this randomized trial advance the treatment paradigms for advanced gastric cancer at ASCO GI 2016
Author: ASCOGI2016
Added: 01/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 22, 2016 Category: Cancer & Oncology Source Type: podcasts
ASCO GI 2016: Does the Asian population differ from the western populations in regards to gastric cancers
Manish Shah, MD of Weill-Cornell Medical Center, NYC answers the question does the Asian population differ from the western populations in regards to gastric cancers at ASCO GI 2016
Author: ASCOGI2016
Added: 01/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 22, 2016 Category: Cancer & Oncology Source Type: podcasts
Andrew H. Ko, MD - Treating Newly Diagnosed Metastatic Pancreatic Cancer: An Oncologist’s View of a Patient’s Story
Treating Newly Diagnosed Metastatic Pancreatic Cancer: An Oncologist’s View of a Patient’s Story (Source: PeerView CME/CE Audio Podcast - Gastroenterology)
Source: PeerView CME/CE Audio Podcast - Gastroenterology - January 18, 2016 Category: Gastroenterology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
William J. Sandborn, MD - Hitting the Target in IBD: A Game-Based Approach to Optimizing the Use of Current Treatments to Achieve Therapeutic Success
Hitting the Target in IBD: A Game-Based Approach to Optimizing the Use of Current Treatments to Achieve Therapeutic Success (Source: PeerView CME/CE Audio Podcast - Gastroenterology)
Source: PeerView CME/CE Audio Podcast - Gastroenterology - December 16, 2015 Category: Gastroenterology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
